Literature DB >> 11924537

Relationships between serum markers of monocyte/macrophage activation in type 1 Gaucher's disease.

J Antonio Casal1, Lúcia Lacerda, Luis F Pérez, Rui A Pinto, M Clara Sá Miranda, J Carlos Tutor.   

Abstract

We studied 44 patients with type 1 Gaucher's disease (16 non-treated patients and 28 treated with enzyme replacement therapy). We measured serum levels of chitotriosidase (ChT), neopterin, angiotensin-converting enzyme (ACE), adenosine deaminase (ADA) and beta-hexosaminidase (Hex) and its major isoenzymes Hex A and Hex B. In the untreated group of patients, the increase in serum levels was ChT>neopterin>ACE> ADA>Hex, with all decreasing significantly in treated patients (p< 0.001). Highly significant correlations were obtained between the markers of monocyte/macrophage activation which were tested (p<0.001). However, partial correlations between serum Hex B (with Hex A constant) and ChT, ACE, neopterin and ADA did not reach statistical significance. This suggests that hepatocytes are the major cellular source of this isoenzyme. Similarly, partial correlation of ChT with neopterin, with the other variables constant, was not significant, which would suggest a different expression of these two markers in Gaucher's disease.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11924537     DOI: 10.1515/CCLM.2002.010

Source DB:  PubMed          Journal:  Clin Chem Lab Med        ISSN: 1434-6621            Impact factor:   3.694


  7 in total

1.  Chitotriosidase activity in plasma and mononuclear and polymorphonuclear leukocyte populations.

Authors:  Lorena Bouzas; J Carlos Guinarte; J Carlos Tutor
Journal:  J Clin Lab Anal       Date:  2003       Impact factor: 2.352

2.  Glucosylceramide transfer from lysosomes--the missing link in molecular pathology of glucosylceramidase deficiency: a hypothesis based on existing data.

Authors:  M Elleder
Journal:  J Inherit Metab Dis       Date:  2006-11-02       Impact factor: 4.982

Review 3.  Paediatric non-neuronopathic Gaucher disease: recommendations for treatment and monitoring.

Authors:  Antonio Baldellou; Generoso Andria; Pauline E Campbell; Joel Charrow; Ian J Cohen; Gregory A Grabowski; Chris M Harris; Paige Kaplan; Kieran McHugh; Eugen Mengel; Ashok Vellodi
Journal:  Eur J Pediatr       Date:  2003-12-16       Impact factor: 3.183

Review 4.  Molecular regulations and therapeutic targets of Gaucher disease.

Authors:  Yuehong Chen; Neetu Sud; Aubryanna Hettinghouse; Chuan-Ju Liu
Journal:  Cytokine Growth Factor Rev       Date:  2018-04-11       Impact factor: 7.638

5.  Chitotriosidase as a biomarker of cerebral adrenoleukodystrophy.

Authors:  Paul J Orchard; Troy Lund; Wes Miller; Steven M Rothman; Gerald Raymond; David Nascene; Lisa Basso; James Cloyd; Jakub Tolar
Journal:  J Neuroinflammation       Date:  2011-10-20       Impact factor: 8.322

6.  Efficacy of serum chitotriosidase activity in early treatment of patients with active tuberculosis and a negative sputum smear.

Authors:  Canturk Tasci; Serkan Tapan; Sevket Ozkaya; Ersin Demirer; Omer Deniz; Arzu Balkan; Metin Ozkan; Ilker Inan; Ismail Kurt; Hayati Bilgic
Journal:  Ther Clin Risk Manag       Date:  2012-08-27       Impact factor: 2.423

7.  Oxidative stress parameters of Gaucher disease type I patients.

Authors:  Alexandre Silva Mello; Cristina da Silva Garcia; Fernanda de Souza Machado; Niara da Silva Medeiros; Mariane Farias Wohlenberg; Jéssica Pereira Marinho; Caroline Dani; Cláudia Funchal; Janice Carneiro Coelho
Journal:  Mol Genet Metab Rep       Date:  2015-05-22
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.